Inmune Bio (0Y2) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Inkmune | Cancer, Metastatic Castration-Resistant Prostate Cancer, Mcrpc | phase1AndPhase2 | Completed | Study of INKmune in Patients With mCRPC (CaRe Prostate) | Aug 07, 2023 | ― |
| Xpro1595 | Mental Disorders, Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders | Phase II | Terminated | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | Aug 18, 2022 | ― |
| Xpro1595 | Neurocognitive Disorders, Mental Disorders, Tauopathies, Neurodegenerative Diseases, Central Nervous System Diseases, Nervous System Diseases, Dementia, Brain Diseases, Mild Cognitive Impairment, Alzheimer Disease | Phase II | Completed | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | Mar 07, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Inkmune | phase1AndPhase2 | Cancer, Metastatic Castration-Resistant Prostate Cancer, Mcrpc | Completed | Study of INKmune in Patients With mCRPC (CaRe Prostate) | Aug 07, 2023 | ― |
| Xpro1595 | Phase II | Mental Disorders, Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders | Terminated | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease | Aug 18, 2022 | ― |
| Xpro1595 | Phase II | Neurocognitive Disorders, Mental Disorders, Tauopathies, Neurodegenerative Diseases, Central Nervous System Diseases, Nervous System Diseases, Dementia, Brain Diseases, Mild Cognitive Impairment, Alzheimer Disease | Completed | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation | Mar 07, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Inmune Bio (DE:0Y2) have in its pipeline
Inmune Bio DE:0Y2 is currently developing the following drugs: Inkmune, Xpro1595. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
